References and Supporting Research

National Headache Foundation
5252 North Western Avenue
Chicago, IL  60625
800-843-2256

American Council for Headache Education (ACHE)
875 Kings Highway Suite 200
Woodbury, NJ  08096
800-255-ACHE

1. Aloisi, P., Marrelli, A., Porto, C., Tozzi, E., Cerone, G. Visual evoked potentials and serum magnesium levels in juvenile migraine patients. Headache 1997 Jun; 37(6): 383-5.
2. Blok, WL, Kata, MB, van der Meer J. Modulation of inflammation and cytokine production by dietary (n-3) fatty acids. J Nutr 1996;126:1515-33.
3. Bucci, LR. Nutrition Applied to Injury Rehabilitation and Sports Medicine. Boca Ranton, FL: CRC Press; 1995.
4. Claustrat, B., Brun, J., Geoffriau, M., Zaidan, R., Mallo, C., Chazot, G. Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. Cephalalgia 1997 Jun; 17(4): 511-7; discussion, 487.
5. Erasmus, U. Fats That Heal, Fats That Kill 2^nd ed. Burnaby BC, Canada: Alive Books; 1993.
6. Feig, C. Dentist Advocates Cold Gel for Migraines 2002. CNN Medical Unit/CNN.com Health (www.cnn.com/2002/HEALTH/conditions/02/11/migraine.treatment/index.html).
7. Grossman, W., Schmidramsl, H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Altern. Med. Rev. 2001 Jun; 6(3): 303-10.
8. James, MJ, Gibson, RA, Clealand, LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000; 71(Suppl):343S-48S.
9. Kremer, JM, Lawrence, DA, Petrillo, GF, et al. Effects of high dose fish oil on rheumatoid arthritis after stopping nonsteroi­dal anti-inflammatory drugs. Arth Rheum 1995;38(8):1107-14.
10. Kunkel, SL, Ogawa, H, Ward, PA, et al. Suppression of chronic inflammation by evening primrose oil. Prog Lipid Res 1982;20:885-88.
11. Lauritzen, C. Results of a 5 year prospective study of estriol succinate treatment in patients with climacteric complaints. Horm. Metab. Res. 1987 Nov; 19(11): 579-84.
12. Mauskop, A., Altura, B.M. Role of magnesium in the pathogenesis and treatment of migraines. Clin. Neurosci. 1998; 5(1): 24-7.
13. Meydani, SN. Effect of (n-3) polyunsaturated fatty acids on cytokine production and their biologic function. Nutr 1996;12:S8-S14.
14. Murphy, J.J., Heptinstall, S., Mitchell, J.R. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988 Jul 23; 2(8604): 189-92.
15. Palevitch, D., Earon, G., Carasso, R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother. Res. 1997; 11(7): 508-11.
16. Pedley, Timothy, MD, chairman, Department of Neurology, Columbia University, New York.
17. Pullman-Mooar, Lapsosta, M, Lem, D, et al. Alteration of the cellular fatty acid profile and the production of eicosanoids in human monocytes by gamma-linolenic acid. Arth Rheum 1990;33(10):1526-33.
18. Rosen, T.D. Coenzyme Q10 may stave off migraine. Cephalalgia 2002 Mar; 22: 137-41; see instead Rozen, T.D., Oshinsky, M.L., Gebeline, C.A., Bradley, K.C., Young, W.B., Shechter, A.L., Silberstein, S.D. Open label trial of coenzyme Q10 as a migraine preventative. Cephalalgia 2002 Mar; 22(2): 137-41.
19. Russell, A.L., McCarty, M.F. Glucosamine for migraine prophylaxis? Med. Hypotheses 2000 Sep; 55(3): 195-8.
20. Sandor, P.S., Afra, J., Ambrosini, A., Schoenen, J. Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials. Headache 2000 Jan; 40(1): 30-5.
21. Schoenen, J., Lenaerts, M., Bastings, E. High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia 1994; 14(5): 328-9.
22. Silberstein, Stephen, MD, director, Thomas Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia.
23. Simopoulos, AP. Omega-3 ftty acids in health and disease and in growth and development. Am J Clin Nutr 1991;54:438-63.
24. Warner, Jennifer. “Taking the Pain Out of Migraine Treatments”, WebMD Medical News, Dec.4, 2003.
25. Welch, K.M. Pathogenesis of migraine. Semin. Neurol. 1997; 17(4): 335-41.

26. Hinz, ML. Migraines. Taken from www.neuroassist.com/migraine.htm on May 14, 2009.

27. JAMA. 2004;291:427-434, 493-494.

28. Kurth T, et al. JAMA 2006;296:283-291.

29. Kurth T, et al. Arch Intern Med. 2007;167:795-801.

30. Bousser MG, et al. Cephalalgia. 2000;20:155-156.

31. MacGregor EA, de Lignieres B. Cephalalgia. 2000;20:157-163.

32. Corvaglia L, et al. Depression in adult untreated celiac subjects: diagnosis by the pediatrician. Am J Gastroenterol. 1999 Mar; 94(3):839-43.

33. Ciacci C, et al. Depressive symptoms in adult coeliac disease. Scand J Gastroenterol. 1998 Mar;33(3):247-50.

34. Addolorato G, et al. Anxiety and depression in adult untreated celiac subjects and in patients affected by inflammatory bowel disease: a personality “trait” or a reactive illness? Hepatogastroenterology. 1996 Nov-Dec;43(12):1513-7.

35. Pellegrino M, et al. Untreated coeliac disease and attempted suicide. Lancet. 1995 Sep 30;346(8979):915.

36. Cheliout W. [A misleading depression]. Encephale. 1994 Sep-Oct;20(5):531-4. French.

37. Hernanz A, et al. Plasma precursor amino acids of central nervous system monoamines in children with coeliac disease. Gut. 1991 Dec;32(12):1478-81.

38. van Praag HM. Affective disorders and aggression disorders: evidence for a common biological mechanism. Suicide Life Threat Behav. 1986 Summer;16(2):103-32. Review.

39. Hallert C, et al. Psychic disturbances in adult coeliac disease. I. Clinical observations. Scand J Gastroenterol. 1982 Jan;17(1):17-9.